FDA Denies Approval of Gefapixant for Chronic Cough

The FDA has issued a CRL to Merck regarding the NDA for gefapixant for the treatment of refractory or unexplained chronic cough in adults.

Related Keywords

Joerg Koglin ,Allergy Drugs Advisory Committee ,Drug Administration ,Merck Research Laboratories ,Complete Response Letter ,New Drug Application ,